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Summary 
Alzheimer’s disease (AD) is a primary cause of dementia in the 
middle-aged and elderly worldwide. Animal models for AD are 
widely used to study the disease mechanisms as well as to test 
potential therapeutic agents for disease modification. Among the 
non-genetically manipulated neuroinflammation models for AD, 
lipopolysaccharide (LPS)-induced animal model is commonly 
used. This review paper aims to discuss the possible factors that 
influence rats’ response following LPS injection. Factors such as 
dose of LPS, route of administration, nature and duration of 
exposure as well as age and gender of animal used should be 
taken into account when designing a study using LPS-induced 
memory impairment as model for AD. 
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Introduction 
 
Alzheimer's disease (AD) was first described  
by Alois Alzheimer in 1906. It is a progressive 
neuropsychiatric disorder characterized by progressive 
loss of cognitive abilities (Wilkins and Brody 1969, 
Cavanaugh et al. 2014). It is a debilitating, ultimately 
fatal disease and is the primary cause of dementia in the 
middle-aged and elderly (Wilkins and Brody 1969, 
Fitzpatrick et al. 2005, Alzheimer’s Disease International 
2009, Cavanaugh et al. 2014). 
The common initial symptoms are forgetfulness 
and difficulties with routine tasks. As the disease 
progresses, patients develop more severe memory loss, 
speech impairment, visual and spatial deficits, and loss of 
coordination and fine motor control (Rossor et al. 1996, 
Alzheimer’s Disease International 2009, Obermeyer et al. 
2012). Besides the cognitive, sensory, and motor deficits 
caused by the disease progression, there are a number of 
behavioral and psychological symptoms related to 
dementia. These symptoms include agitation and 
aggression, wandering, disturbances in the sleep cycle, 
depression, anxiety, delusions and hallucinations (Ferri et 
al. 2004, de Vugt et al. 2005, Obermeyer et al. 2012). 
AD reduces the life expectancy of those affected, with  
an average survival time after diagnosis of 5-7 years 
(Fitzpatrick et al. 2005, Ganguli et al. 2005). 
AD can be categorized into early and late onset. 
Early-onset AD (EOAD) typically begins between the 
ages of 30 and 60 years, and accounts for fewer than 5 % 
of AD cases. The more common form, late-onset or 
sporadic AD (LOAD), presents after the age of 65 
(Rossor et al. 1996, Irvine et al. 2008).  
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Risk factors for Alzheimer’s Disease 
 
The single greatest risk factor for developing AD 
is age, with a risk of 10 % for persons older than 65 years 
and nearly 50 % for those older than 85 years (Rossor et 
al. 1996, Gatz et al. 2006, Chai 2007). 
Apart from age, genetic component is another 
risk factor for AD. Autosomal dominant familial AD 
(FAD), which is typically an EOAD, has been linked to 
mutations in genes encoding presenilin1 (PSEN1), 
presenilin2 (PSEN2), and beta-amyloid precursor protein 
(APP) (Chartier-Harlin et al. 1991, Goate et al. 1991, 
Mullan et al. 1992, Schellenberg et al. 1992, Levy-Lahad 
et al. 1995, Sherrington et al. 1995). Inheritance of the 
apolipoprotein E type 4 allele (ApoE4) may also increase 
the risk of developing sporadic LOAD, though ApoE4 
alone is neither necessary nor sufficient to cause AD 
(Corder et al. 1993, Strittmatter et al. 1993, Rossor et al. 
1996, Sadigh-Eteghad et al. 2012). 
 
Non-genetically manipulated  
neuro-inflammation models for AD 
 
The unique neuropathological hallmarks of AD 
are extracellular accumulation of beta-amyloid (Aβ) 
peptide and intracellular accumulation of 
hyperphosphorylated tau protein or neurofibrillary tangles 
(NFTs,) (Hardy and Selkoe 2002, Iqbal and Grundke-
Iqbal 2006). A true model that fits the inflammation 
hypothesis of AD is an aged animal (older than 
22 months) that manifests early chronic neuro-
inflammation lasting more than 7 days prior to 
hyperphosphorylation of tau and Aβ plaque deposition 
(Burton and Johnson 2012).  
The intracellular accumulation of Aβ, especially 
Aβ1-42, has been shown to precede the formation of 
extracellular amyloid deposits in subjects with AD and 
trisomy 21 (Gouras et al. 2000), in brains of young 
Tg mice (8-month-old) harboring APP with three  
FAD-linked mutations (KM670/671NL, E693Q, and 
V7171) and the PS1 mutation M146L (Wirths et al. 2001), 
and in the brains of older Tg mice (17-month-old) 
harboring various FAD-linked PS1 mutations (Chui et al. 
1999). Based on these findings, Sheng et al. (2003) 
concluded that intracellular accumulation of Aβ may be an 
early stage of a process that may eventually lead to 
extracellular amyloid deposits and the formation of 
plaques. 
However, other potential rodent models of AD 
that present with early neuroinflammation in the disease 
process and are not genetically manipulated by mutations 
related to Aβ or tau production are also commonly used. 
These include lipopolysaccharide (LPS)-, polyI C-, 
streptozotocin-, okadaic acid- and colchicine-induced 
neuroinflammation. LPS-induced neuroinflammation 
represents the current standard paradigm to study 
neuroinflammation both in vivo (Hauss-Wegrzyniak et al. 
1998, Sheng et al. 2003, Anaeigoudari et al. 2016) and 
in vitro (Candiracci et al. 2012). There are several other 
non-genetically manipulated rat models of AD which are 
not limited to induced neuroinflammation. For example, 
the ferrous amyloid buthionine (FAB) rat model (Lecanu 
and Papadopoulos 2013), the sodium azide model 
(Szabados et al. 2004) and the Samaritan AD rat model 
(Petrasek et al. 2016). This review focuses only on the 
widely studied LPS-induced cognitive deficit in rats and 
the possible factors that can influence rats’ response to 
LPS. 
 
Lipopolysaccharide  
 
LPS is used worldwide in experimental in vitro 
and in vivo models of neuroinflammation and amyloidosis 
(Miklossy 2008). LPS-induced systemic inflammation is 
used in a number of neurodegenerative diseases; AD 
(Hauss-Wegrzyniak et al. 1998; Sheng et al. 2003; 
Anaeigoudari et al. 2016), Parkinson disease (Gao et al. 
2002; Whitton 2007), amyotrophic lateral sclerosis (Zhao 
et al. 2004) and multiple sclerosis (Walter et al. 2006).  
LPS is a component of the outer membrane of 
gram-negative bacteria. It is a potent endotoxin and is 
highly resistant to degradation by mammalian enzymes 
thus providing a persistent inflammatory stimulus 
(Ohanian and Schwab 1967) that produces 
proinflammatory cytokines. These proinflammatory 
cytokines activate both the neuroimmune and 
neuroendocrine systems (Maitra et al. 2012) that result in 
similar responses as produced by behavioral stress (Oitzl 
et al. 1993). 
LPS produces a wide range of non-specific 
behavioral effects collectively termed ‘sickness 
behaviors’ (Klein and Nelson 1999). These behaviors 
include reduction in activity, reduction in exploration, 
decreased social interaction, fever, reduction in 
consumption of food and drink, hypersomnia, activation 
of the hypothalamic-pituitary-adrenal (HPA) axis and 
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causing increased sympathetic activation (Hart 1988, 
Kebt et al. 1992, Pugh et al. 1998). 
 
Mechanism of action of LPS in the central 
nervous system (CNS) 
 
A direct action of LPS within the CNS is  
an important possibility (Elmquist et al. 1997). It is 
possible that LPS can access the brain directly via 
peripheral nerve transduction (Hansen et al. 2000), the 
circumventricular organs (Blatteirs et al. 1992), area 
postrema (Ericsson et al. 1994) or even at the level of the 
hypothalamus (Yasuda and Greer 1978, Zhang et al. 2000). 
Mechanism of LPS action in CNS is shown in Figure 1. 
 
 
 
 
Fig. 1. Mechanism of LPS action in CNS. 
 
 
LPS binds CD14 on microglia membranes 
forming the LPS-CD14 complex which then interacts 
with toll-like receptor (TLR)-4 (Hailman et al. 1994, 
Lehnardt et al. 2003). TLR-4, in turn, activates microglia 
by initiating signal transduction cascades leading to rapid 
transcription and release of proinflammatory cytokines 
including interleukin (IL)-1, IL-6, IL-12, IL-17A, IL-18, 
p40, inducible nitric oxide synthase (iNOS) and tumor 
necrosis factor-α (TNF-α) (Rivest 2009, Bossu et al. 
2012, Sun et al. 2015); chemokines such as CCL2, 
CCL5, and CXCL8; complement system proteins such as 
C3, C3a, and C5a receptors (Rivest 2009); and  
anti-inflammatory cytokines such as IL-10 (Mizuno et al. 
1994) and transforming growth factor-β (TGF-β) 
(Welser-Alves and Milner 2013). It has been shown that 
the level of expression of TNF-α, IL-1β, and IL-6 in the 
hippocampus was increased compared to controls after 
three days of LPS administration (Daulatzai 2016). 
Proinflammatory cytokines are key molecules 
that modulate immune responses. Their lack of 
reversibility in chronic inflammation would enhance 
dyshomeostasis (Ghosh et al. 2015). Chronic 
inflammation is characterized by long-standing activation 
of microglia that sustains the release of inflammatory 
mediators, leading to an increase of oxidative and 
nitrosative stress. This perpetuates the inflammatory 
cycle (Tansey et al. 2007), further prolonging the 
inflammation (Schmid et al. 2009) that is detrimental for 
several neurodegenerative diseases (Block and Hong 
2005). 
An excessive inflammatory response is 
characterized not only by elevated proinflammatory 
cytokines, but also by increases in mitochondrial 
dysfunction, reactive oxygen species (ROS), and nitric 
oxide (NO). Consequently, there may be damage to the 
systemic vascular endothelium, redox-glutathione 
depletion, and mitochondrial respiratory dysfunction 
causing reduction in ATP and O2 consumption. Hence, 
inflammation and oxidative stress are intertwined (Exline 
and Crouser 2008, Bivalacqua et al. 2009, Victor et al. 
2009, Galley 2011, Lowes et al. 2013) and have been 
implicated in the pathophysiology of AD.  
It has been shown that inflammatory cytokines 
such as IL-1β, IL-6, TNF-α and TGF-β can augment APP 
expression (Buxbaum et al. 1992, Hirose et al. 1994) and 
Aβ formation (Blasko et al. 1999). It has also been 
reported that cytokines are able to transcriptionally 
upregulate β-secretase mRNA, protein and enzymatic 
activity (Sastre et al. 2003). β-secretase is a key  
rate-limiting enzyme that initiates Aβ formation (Vassar 
2001). Without β-secretase, Aβ synthesis is either 
abolished or considerably reduced (Walter et al. 2001).  
It has been pointed out in the literature that  
LPS-induced inflammation promotes AD pathology by 
altering Aβ transport at the blood brain barrier (BBB) 
(Jaeger et al. 2009) and decreasing the central clearance 
of Aβ (Erickson et al. 2012). Alteration of BBB 
effectively increases brain influx of Aβ but decreases its 
efflux (Jaeger et al. 2009). The level of expression of Aβ 
in the hippocampus is shown to increase (compared with 
controls) after seven days of LPS administration 
(Daulatzai 2016). 
LPS-induced neuronal cell death could be the 
result of cyclooxygenase-2 (COX-2) and extracellular 
signal-regulated kinase (ERK) activation (Lee et al. 
556   Zakaria et al.  Vol. 66 
 
 
2008). COX-2 is barely detectable under normal 
physiological conditions, but can be induced rapidly and 
transiently by proinflammatory mediators and mitogenic 
stimuli, thereby mediating deleterious effects in the 
neurodegenerative disorders (Pasinetti et al. 2001). In 
Alzheimer brain, COX-2 is notably up-regulated, which 
seems to be associated with Aβ plaque formation 
(Pasinetti et al. 1998, Hoozemans et al. 2001, Pasinetti et 
al. 2002). Conversely, deposition of Aβ in the brain has 
been reported to trigger an inflammatory response 
associated with the neuropathophysiology of AD (Paris et 
al. 2002). Jang and Surh (2005) showed that Aβ-induced 
apoptosis is associated with COX-2 up-regulation 
through activation of NF-κB, which is mediated by 
upstream kinases including ERK and p38 mitogen-
activated protein kinases (MAPK).  
LPS may disrupt the consolidation of certain 
memory processes. Acute administration of LPS prior to 
training impairs contextual-cue fear conditioning, 
a hippocampal-dependent learning paradigm (Pugh et al. 
1998); while chronic infusion of LPS has been found to 
impair spatial memory (Hauss-Wegrzyniak et al. 1998, 
Hauss-Wegrzyniak et al. 2000) and induce memory and 
learning deficits analogous to AD cognitive decline  
(Lee et al. 2008). Systemic LPS administration leads to 
selective hippocampal impairment in context-object 
discrimination but not spatial memory (Czerniawski et al. 
2015). Major cognitive findings in LPS-treated rats are 
summarized in Table 1. 
 
Animal response following LPS 
administration 
 
There are a number of factors that can influence 
animal response to LPS injections, including dose, nature 
of exposure, route of administration, duration of 
exposure, age and gender of the animals.  
 
Dose of LPS  
Houdek et al. (2014) demonstrated that direct 
LPS infusion into the fourth ventricle of the male rat 
brain resulted in a dose-dependent response of activated 
microglia and astrocyte. Very low-dose LPS infusion 
(0.05 ng/h) was sufficient to induce neuroglial activation 
while moderate and high doses (50 ng/h and above) were 
required to induce significant loss of choline 
acetyltransferase (ChAT)-positive cells in the basal 
forebrain. 
Nature of LPS exposure 
Pugh et al. (1998) demonstrated that 0.125 and 
0.25 mg/kg LPS interfered with contextual fear 
conditioning, while 0.5 mg/kg had no effect. Similarly, 
LPS differentially affects the hypothalamic-pituitary axis 
in that a higher dose of LPS stimulates the sustained 
release of corticosterone (Nguyen et al. 1998, Pugh et al. 
1998). This appears to be only true for acute exposure to 
LPS; repeated injections of LPS have no such effect on 
corticosterone levels (Takemura et al. 1997).  
Later studies by Shaw et al. (2001) showed that 
a single injection of LPS impaired escape latency in both 
the acquisition and retention phases of the Morris water 
maze while a daily injection did not. Repeated  
LPS exposure also resulted in lower IL-1β activation; this 
may be due to an alteration in peripheral sympathetic 
responsiveness (Zhang et al. 2000). It is possible that 
repeated exposure to LPS produces a tolerance effect, as 
suggested by the lower IL-1β activation, which may 
account for the observed behavioral changes in the study. 
Repeated endotoxin exposure has long been 
known to result in a tolerance-like phenomenon (Habicht 
1981). The acute administration of LPS has been better 
characterized, and a few studies have examined the 
effects of repeated LPS injections upon behavior or how 
endotoxin tolerance may be observed in terms of an 
animal’s learning. Kobayashi et al. (2002) demonstrated 
at least one of the molecular bases for the tolerance-like 
phenomenon. They showed that repeated stimulation of 
the TLR results in the induction of IL-1 receptor 
associated kinase-M (IRAK-M), negatively regulating the 
TLR signaling cascade by halting IRAK’s interaction 
with TNF-receptor associated factor-6 (TRAF6). This 
mechanism of tolerance may be an adaptive event critical 
in avoiding endotoxic shock.  
 
Route of LPS administration  
The most common routes of LPS administration 
for LPS-induced cognitive impairment rat model are 
intraperitoneal and intracerebroventricular. However, we 
found no studies that explicitly compare different routes 
of LPS administration with the effect of cognitive 
function in rats. 
 
Duration of LPS exposure 
Bordou and colleagues (2014) investigated the 
role of duration of exposure to LPS on the 
neuroinflammatory response to LPS. Male rats received 
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continuous infusion of picomolar levels of LPS (or 
artificial CSF as control) into their fourth ventricle for 
either 3 or 8 weeks. Longer duration of exposure to LPS 
infusion further increased the elevated levels of IL-1-α, 
IL-2, IL-4, IL-5, IL-6, IL-12, IL-13, and GM-CSF. This 
study provides evidence of the influence of chronicity of 
infection on neuroinflammatory responses in certain brain 
regions, such as locus coeruleus, that undergo significant 
cell loss in the early stages of AD (Grudzien et al. 2007). 
However, the study did not investigate the role of 
duration of exposure to LPS on cognitive behavior. 
In a study of Zhu et al. (2014), the results 
demonstrated that 7 days of LPS administration 
significantly increased the latency to the platform and 
decreased the proportion of time spent in the target 
quadrant during Morris water maze test, compared to 
3 days of LPS administration. Increased expression 
of Aβ in the hippocampus was observed following 
administration of LPS for 7 days, but not for 3 days, 
indicating that the increased expression of Aβ may be 
a major factor in the pathogenesis of cognitive 
dysfunction. 
Age of animal during LPS exposure 
Age appears to be an important factor 
influencing the behavioral responses to LPS. Prenatal 
(Bakos et al. 2004) and early postnatal (Fan et al. 2005, 
Pang et al. 2006) LPS exposure has been shown to induce 
poor neurobehavioral performance and is frequently used 
to model diseases such as schizophrenia and autism 
(Powell 2010, Meyer 2014, Waterhouse et al. 2016). 
Younger animals seem to be affected to a lesser 
degree, at a slower pace and do not show speed 
decrement on day one as shown by the year-old mice 
(Sparkman et al. 2005). Bardou and colleagues (2014) 
investigated the age of exposed rats on the 
neuroinflammatory response to LPS. Male rats at three 
age groups of young (3 months), middle-aged (9 months), 
and aged (23 months) received continuous infusion of 
picomolar levels of LPS (or artificial CSF as control) into 
their fourth ventricle. Among all cytokines, TNF-α 
increase in response to LPS infusion was similar in the 
different age groups. However, in contrast to young rats, 
IL-1β did not significantly increase after 3 weeks of 
infusion in middle-aged and aged rats. Instead, aged rats 
had significantly increased IFN-γ compared to younger 
rats. However, in another study LPS administration in 
aged rats induced prolonged neuroinflammation and 
astrogliosis in the hippocampus (dentate gyrus) with 
higher mRNA expression and protein levels of TNF-α 
and IL-1β (Fu et al. 2014). 
Age is also an important factor to develop 
tolerance-like phenomenon (Habicht 1985). Splenic 
lymphocytes of 12-month and 24-month-old animals are 
less likely to develop tolerance following repeated 
endotoxin exposure when compared to splenic 
lymphocytes obtained from young animals. Thus, old 
animals exposed to long-term LPS seem to be an ideal 
model of AD. 
Gender 
Almost all rat studies of LPS-induced cognitive 
impairment model used male rats. However, studies in 
mice demonstrated a heightened HPA response to LPS in 
females (Frederic et al. 1993, Spinedi et al. 1997), which 
may have important behavioral implications. 
Conclusion 
Extra caution is needed before extrapolating 
preclinical findings using LPS to clinical situations. 
Sensitivity to LPS and the consequent production of 
proinflammatory cytokines is much greater in humans 
compared to rodents (Warren et al. 2010). Thus, the 
doses of LPS given in most rodent models are about 
103-104 times the dose required to induce severe disease 
in humans (Sauter et al. 1980, Taveira et al. 1993). Other 
factors such as route of administration, nature and 
duration of exposure as well as age and gender of animal 
used should be taken into account when designing a study 
using LPS-induced memory impairment as model 
for AD. 
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